ARCHIVES

Extent Of Risk Reduction From Ovary Removal Varies According To BRCA Mutation

This article is from The Cancer Letter archive.

Vol. 31 No. 2 | February 29, 2008

Download PDF Visit The Full Archive

Related Articles

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

September 28, 2012

Tasigna Wins New Indication For CML; Jevtana Approved For Prostate Cancer

June 18, 2010

Continuing Resolution Funds Agencies Through Dec. 5.

November 17, 2000

The Number of Adult Cooperative Groups Drops to Four As NSABP, RTOG And GOG Agree to Merge

October 21, 2011

Abbott Offers New Education Awards

June 12, 1987

Growth in Research Capacity Explains Increased Competition, NIH Director Tells NCAB.

June 16, 2006